Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.37 |
| ▸ | TACR1 | P25103 | 2/20 | 0.36 |
| ▸ | CCR3 | P51677 | 3/20 | 0.35 |
| ▸ | CCR5 | P51681 | 3/20 | 0.35 |
| ▸ | REN | P00797 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | RPLP1 | P05386 | 2/20 | 0.34 |
| ▸ | RPLP0 | P05388 | 2/20 | 0.34 |
| ▸ | RPS17 | P08708 | 2/20 | 0.34 |
| ▸ | RPSA | P08865 | 2/20 | 0.34 |
| ▸ | RPS2 | P15880 | 2/20 | 0.34 |
| ▸ | RPL35A | P18077 | 2/20 | 0.34 |
| ▸ | RPL7 | P18124 | 2/20 | 0.34 |
| ▸ | RPL17 | P18621 | 2/20 | 0.34 |
| ▸ | RPS4Y1 | P22090 | 2/20 | 0.34 |
| ▸ | RPS3 | P23396 | 2/20 | 0.34 |
| ▸ | RPS12 | P25398 | 2/20 | 0.34 |
| ▸ | RPL13 | P26373 | 2/20 | 0.34 |
| ▸ | RPL10 | P27635 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23428930 | 0.92 | HCRTR1 (0.36) | ACHEHCRTR1TACR1CCR3CCR5 | |
| SCHEMBL4194732 | 0.91 | KCNH2 (0.37) | ACHECCR3CCR5RENCYP3A4 | |
| SCHEMBL2083942 | 0.91 | HCRTR1 (0.37) | ACHEHCRTR1CCR3RENCYP3A4 | |
| SCHEMBL2084600 | 0.88 | MEN1 (0.42) | ACHE | |
| SCHEMBL2081809 | 0.85 | MAPK8 (0.37) | HCRTR1RENCYP3A4MALT1 | |
| SCHEMBL2084364 | 0.83 | SLC6A2 (0.38) | ACHETACR1RENCYP3A4KCNH2 | |
| SCHEMBL5053655 | 0.82 | CXCR4 (0.35) | CCR5CYP3A4KCNH2 | |
| SCHEMBL2083524 | 0.81 | OPRL1 (0.36) | CCR5RENCYP3A4RPLP1RPLP0 | |
| SCHEMBL5053645 | 0.81 | NPY2R (0.35) | CCR3CCR5CYP3A4KCNH2DRD4 | |
| SCHEMBL2086585 | 0.79 | MEN1 (0.43) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255197-A1 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED CORPORATION (CA) | 2008-10-16 | — | — | US | claimed |
| US-7291631-B2 | CXCR4 chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2007-11-06 | — | — | US | claimed |
| EP-1613613-B1 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | GENZYME CORP (US) | 2021-06-02 | — | — | EP | disclosed |
| US-20080255197-A1 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED CORPORATION (CA) | 2008-10-16 | — | — | US | disclosed |
| US-7291631-B2 | CXCR4 chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2007-11-06 | — | — | US | disclosed |
| US-20040209921-A1 | CXCR4 chemokine receptor binding comounds | ANORMED CORPORATION (CA) | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209921-A1 | CXCR4 chemokine receptor binding comounds | CXCR4, CXCR1, CXCR3 | ACHE 3926/4885HCRTR1 121/4885TACR1 84/4885 |
| US-20080255197-A1 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | CXCR4, CXCR1, CXCR3 | ACHE 3767/4885HCRTR1 155/4885TACR1 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.